U.S., Feb. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07397325) titled 'Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia' on Feb. 02.
Brief Summary: Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia
Study Start Date: March 16
Study Type: INTERVENTIONAL
Condition:
Chemotherapy Induced Alopecia
Chemotherapy Side Effects
Intervention:
DRUG: DA-020
Topical Oxymetazoline 7mL
DRUG: Placebo
Topical placebo solution
DRUG: DA-020 and Hyperforin (1.5%)
7mL Topical Oxymetazoline + Hyperforin (1.5%)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Applied Biology, Inc.
Disclaimer: Curated by HT Syndication....